TWST Twist Bioscience Corp

Nasdaq twistbioscience.com


$ 26.26 $ 0.62 (2.44 %)    

Thursday, 20-Nov-2025 15:55:36 EST
QQQ $ 586.35 $ -14.20 (-2.37 %)
DIA $ 458.44 $ -3.66 (-0.79 %)
SPY $ 653.33 $ -10.10 (-1.52 %)
TLT $ 89.27 $ 0.35 (0.39 %)
GLD $ 374.78 $ -0.11 (-0.03 %)
$ 26.07
$ 26.44
$ 26.23 x 160
$ 26.24 x 125
$ 25.90 - $ 28.15
$ 23.30 - $ 55.33
2,102,958
na
1.56B
$ 2.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-17-2025 09-30-2025 10-K
2 08-04-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 02-03-2025 12-31-2024 10-Q
5 11-18-2024 09-30-2024 10-K
6 08-02-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-02-2024 12-31-2023 10-Q
9 11-21-2023 09-30-2023 10-K
10 08-07-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-07-2023 12-31-2022 10-Q
13 11-28-2022 09-30-2022 10-K
14 08-08-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-09-2022 12-31-2021 10-Q
17 11-23-2021 09-30-2021 10-K
18 08-09-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-Q
21 11-27-2020 09-30-2020 10-K
22 08-12-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 02-10-2020 12-31-2019 10-Q
25 12-13-2019 09-30-2019 10-K
26 08-09-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-11-2019 12-31-2018 10-Q
29 12-20-2018 09-30-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-twist-bioscience-lowers-price-target-to-37

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $4...

 twist-bioscience-eyes-profit-turnaround-in-2026-after-narrowing-losses

Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus.

 twist-bioscience-sees-q1-sales-100000m-101000m-vs-100337m-est

Twist Bioscience (NASDAQ:TWST) sees Q1 sales of $100.000 million-$101.000 million vs $100.337 million analyst estimate.

 twist-bioscience-sees-fy2026-sales-425000m-435000m-vs-374691m-est

Twist Bioscience (NASDAQ:TWST) sees FY2026 sales of $425.000 million-$435.000 million vs $374.691 million analyst estimate.

 twist-bioscience-q4-eps-045-misses-043-estimate-sales-99009m-beat-97317m-estimate

Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(...

 stephens--co-initiates-coverage-on-twist-bioscience-with-overweight-rating-announces-price-target-of-41

Stephens & Co. analyst Steven Etoch initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Overweight rating and an...

 cathie-wood-warns-wall-street-is-missing-ais-biggest-opportunity-in-healthcare-calling-it-sleeper-investment-poised-for-massive-returns

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its p...

 evercore-isi-group-maintains-outperform-on-twist-bioscience-lowers-price-target-to-42

Evercore ISI Group analyst Vijay Kumar maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price targe...

 twist-bioscience-and-element-biosciences-launch-rapid-trinity-freestyle-workflow-enabling-end-to-end-sequencing-in-5-hours-on-aviti-platforms

-- Launch of End-to-End Workflow for AVITI and AVITI24™ Enabling Sample to Sequencer in as Little as Five Hours ---- Twist Gain...

 cathie-woods-ark-dumps-block-stock-worth-48-million-as-bitcoin-heavy-company-preps-q2-results

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

 update-twist-bioscience-reported-q3-adj-eps-047-beats-055-estimate

Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0....

 twist-bioscience-turns-the-tide-q3-sales-jump-beats-earnings

Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA...

 twist-bioscience-sees-q4-sales-96000m-98000m-vs-99174m-est

For the fourth quarter, Twist expects: • Total revenue of approximately $96 million to $98 millionSynBio revenue of approximate...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION